- Amended Statement of Changes in Beneficial Ownership (4/A)
30 März 2010 - 11:42PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Expires:
February 28, 2011
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Willms Arthur H
|
2. Issuer Name
and
Ticker or Trading Symbol
ANGIOTECH PHARMACEUTICALS INC
[
ANPI
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__
X
__ Director
_____ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Last)
(First)
(Middle)
1618 STATION STREET
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
12/10/2009
|
(Street)
VANCOUVER, A1 V6A 1B6
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
12/14/2009
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option with Tandem SAR
|
$1.41
(1)
|
12/10/2009
|
|
A
|
|
12500
|
|
1/1/2010
(2)
|
12/9/2014
|
Common Stock
|
12500
(3)
|
$0
|
57500
(4)
|
D
|
|
Explanation of Responses:
|
(
1)
|
Canadian $.
|
(
2)
|
The options will start to vest effective 01/01/2010 in equal monthly installments until 06/01/2010.
|
(
3)
|
Represents the number of the Company's common shares into which the stock options are convertible. In the event that the Reporting Person elects to exercise the tandem SAR, the stock option will be canceled and the Reporting Person will be entitled to receive a number of common shares with an aggregate value equal to the product of (a) the excess of the market price of a common share on the date of exercise over the exercise price of the tandem SAR, multiplied by (b) the number of tandem SARs exercised.
|
(
4)
|
The Reporting Person is filing this Form 4/A to amend the Form 4 filed on December 14, 2009 to reduce the total number of derivative securities beneficially owned as a result of the inadvertent inclusion of 5,000 stock options with tandem SARs that had previously expired.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Willms Arthur H
1618 STATION STREET
VANCOUVER, A1 V6A 1B6
|
X
|
|
|
|
Signatures
|
/s/David McMasters, Attorney-in-Fact
|
|
3/30/2010
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere News-Artikel